BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kevadiya BD, Ottemann BM, Thomas MB, Mukadam I, Nigam S, McMillan J, Gorantla S, Bronich TK, Edagwa B, Gendelman HE. Neurotheranostics as personalized medicines. Adv Drug Deliv Rev 2019;148:252-89. [PMID: 30421721 DOI: 10.1016/j.addr.2018.10.011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
Number Citing Articles
1 Miao YB, Zhao W, Renchi G, Gong Y, Shi Y. Customizing delivery nano-vehicles for precise brain tumor therapy. J Nanobiotechnology 2023;21:32. [PMID: 36707835 DOI: 10.1186/s12951-023-01775-9] [Reference Citation Analysis]
2 Zhou Z, Shi B, Xu Y, Zhang J, Liu X, Zhou X, Feng B, Ma J, Cui H. Neural stem/progenitor cell therapy for Alzheimer disease in preclinical rodent models: a systematic review and meta-analysis. Stem Cell Res Ther 2023;14:3. [PMID: 36600321 DOI: 10.1186/s13287-022-03231-1] [Reference Citation Analysis]
3 Rahman M. Magnetic resonance imaging in personalized medicine. Metabolomics 2023. [DOI: 10.1016/b978-0-323-99924-3.00001-7] [Reference Citation Analysis]
4 Neha, Parvez S. Emerging therapeutics agents and recent advances in drug repurposing for Alzheimer's disease. Ageing Res Rev 2022;85:101815. [PMID: 36529440 DOI: 10.1016/j.arr.2022.101815] [Reference Citation Analysis]
5 Myung N, Jin S, Cho HJ, Kang HW. User-designed device with programmable release profile for localized treatment. J Control Release 2022;352:685-99. [PMID: 36328077 DOI: 10.1016/j.jconrel.2022.10.054] [Reference Citation Analysis]
6 Pricope CV, Tamba BI, Stanciu GD, Cuciureanu M, Neagu AN, Creanga-murariu I, Dobrovat B, Uritu CM, Filipiuc SI, Pricope B, Alexa-stratulat T. The Roles of Imaging Biomarkers in the Management of Chronic Neuropathic Pain. IJMS 2022;23:13038. [DOI: 10.3390/ijms232113038] [Reference Citation Analysis]
7 Arrué L, Cigna-Méndez A, Barbosa T, Borrego-Muñoz P, Struve-Villalobos S, Oviedo V, Martínez-García C, Sepúlveda-Lara A, Millán N, Márquez Montesinos JCE, Muñoz J, Santana PA, Peña-Varas C, Barreto GE, González J, Ramírez D. New Drug Design Avenues Targeting Alzheimer's Disease by Pharmacoinformatics-Aided Tools. Pharmaceutics 2022;14:1914. [PMID: 36145662 DOI: 10.3390/pharmaceutics14091914] [Reference Citation Analysis]
8 Golubev AM. Personalized Critical Care Medicine (Review). Obŝaâ reanimatologiâ 2022;18:45-54. [DOI: 10.15360/1813-9779-2022-4-45-54] [Reference Citation Analysis]
9 Zhu J, Wang J, Chen R, Feng Q, Zhan X. Cellular Process of Polystyrene Nanoparticles Entry into Wheat Roots. Environ Sci Technol 2022;56:6436-44. [PMID: 35475335 DOI: 10.1021/acs.est.1c08503] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Aggarwal N, Choudhury S, Chibh S, Panda JJ. Aptamer-nanoconjugates as emerging theranostic systems in neurodegenerative disorders. Colloid and Interface Science Communications 2022;46:100554. [DOI: 10.1016/j.colcom.2021.100554] [Reference Citation Analysis]
11 Akbarian M, Gholinejad M, Mohammadi-samani S, Farjadian F. Theranostic mesoporous silica nanoparticles made of multi-nuclear gold or carbon quantum dots particles serving as pH responsive drug delivery system. Microporous and Mesoporous Materials 2022;329:111512. [DOI: 10.1016/j.micromeso.2021.111512] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
12 Kabay G, Manz A, Dincer C. Microfluidic Roadmap for Translational Nanotheranostics. Small Methods 2021;:e2101217. [PMID: 34957704 DOI: 10.1002/smtd.202101217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Thangam R, Paulmurugan R, Kang H. Functionalized Nanomaterials as Tailored Theranostic Agents in Brain Imaging. Nanomaterials (Basel) 2021;12:18. [PMID: 35009968 DOI: 10.3390/nano12010018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Gupta S, Sharma U. Metabolomics of neurological disorders in India. Analytical Science Advances 2021;2:594-610. [DOI: 10.1002/ansa.202000169] [Reference Citation Analysis]
15 Cai R, Xiang H, Yang D, Lin KT, Wu Y, Zhou R, Gu Z, Yan L, Zhao Y, Tan W. Plasmonic AuPt@CuS Heterostructure with Enhanced Synergistic Efficacy for Radiophotothermal Therapy. J Am Chem Soc 2021;143:16113-27. [PMID: 34582167 DOI: 10.1021/jacs.1c06652] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 11.5] [Reference Citation Analysis]
16 Kiwumulo HF, Muwonge H, Ibingira C, Kirabira JB, Ssekitoleko RT. A systematic review of modeling and simulation approaches in designing targeted treatment technologies for Leukemia Cancer in low and middle income countries. Math Biosci Eng 2021;18:8149-73. [PMID: 34814293 DOI: 10.3934/mbe.2021404] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zhang L, Sun H, Zhao J, Lee J, Ee Low L, Gong L, Chen Y, Wang N, Zhu C, Lin P, Liang Z, Wei M, Ling D, Li F. Dynamic nanoassemblies for imaging and therapy of neurological disorders. Adv Drug Deliv Rev 2021;175:113832. [PMID: 34146626 DOI: 10.1016/j.addr.2021.113832] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Yu TW, Lane HY, Lin CH. Novel Therapeutic Approaches for Alzheimer's Disease: An Updated Review. Int J Mol Sci 2021;22:8208. [PMID: 34360973 DOI: 10.3390/ijms22158208] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
19 Nguyen TT, Nguyen TTD, Nguyen TKO, Vo TK, Vo VG. Advances in developing therapeutic strategies for Alzheimer's disease. Biomedicine & Pharmacotherapy 2021;139:111623. [DOI: 10.1016/j.biopha.2021.111623] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
20 Shende P, Trivedi R. Nanotheranostics in epilepsy: A perspective for multimodal diagnosis and strategic management. Nano Select 2021;2:1277-1290. [DOI: 10.1002/nano.202000141] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Vargas Garcia MA, Bustamante Arboleda V, Ospina Ruiz A, Valvuena Cuartas C. Abordaje Rehabilitador de la Deglución en Adultos Mayores con Enfermedades Neurodegenerativas: Revisión Sistemática: Revisión sistemática. Rev Areté 2021;21:55-64. [DOI: 10.33881/1657-2513.art21105] [Reference Citation Analysis]
22 Vargas Garcia MA, Bustamante Arboleda V, Ospina Ruiz A, Valvuena Cuartas C. Abordaje Rehabilitador de la Deglución en Adultos Mayores con Enfermedades Neurodegenerativas: Revisión Sistemática: Revisión sistemática. Rev Areté 2021;21:55-64. [DOI: 10.33881/1657-2513.art.21105] [Reference Citation Analysis]
23 George Kerry R, Ukhurebor KE, Kumari S, Maurya GK, Patra S, Panigrahi B, Majhi S, Rout JR, Rodriguez-Torres MDP, Das G, Shin HS, Patra JK. A comprehensive review on the applications of nano-biosensor-based approaches for non-communicable and communicable disease detection. Biomater Sci 2021;9:3576-602. [PMID: 34008586 DOI: 10.1039/d0bm02164d] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
24 Walter FR, Santa-Maria AR, Mészáros M, Veszelka S, Dér A, Deli MA. Surface charge, glycocalyx, and blood-brain barrier function. Tissue Barriers 2021;:1904773. [PMID: 34003072 DOI: 10.1080/21688370.2021.1904773] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
25 Cheng JL, Dibble EH, Baird GL, Gordon LL, Hyun H. Diversity, Equity, and Inclusion in Academic Nuclear Medicine: National Survey of Nuclear Medicine Residency Program Directors. J Nucl Med 2021;62:1207-13. [PMID: 33893194 DOI: 10.2967/jnumed.120.260711] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Moorthy H, Govindaraju T. Dendrimer Architectonics to Treat Cancer and Neurodegenerative Diseases with Implications in Theranostics and Personalized Medicine. ACS Appl Bio Mater 2021;4:1115-39. [PMID: 35014470 DOI: 10.1021/acsabm.0c01319] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
27 Shinn J, Lee S, Lee HK, Ahn J, Lee SA, Lee S, Lee Y. Recent progress in development and applications of second near-infrared (NIR-II) nanoprobes. Arch Pharm Res 2021;44:165-81. [PMID: 33538959 DOI: 10.1007/s12272-021-01313-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
28 Perrelli A, Fatehbasharzad P, Benedetti V, Ferraris C, Fontanella M, De Luca E, Moglianetti M, Battaglia L, Retta SF. Towards precision nanomedicine for cerebrovascular diseases with emphasis on Cerebral Cavernous Malformation (CCM). Expert Opin Drug Deliv 2021;18:849-76. [PMID: 33406376 DOI: 10.1080/17425247.2021.1873273] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
29 Chintamaneni PK, Krishnamurthy PT, Sathyamoorthy N. Nanocarriers for theranostic applications. Nanocarriers for the Delivery of Combination Drugs 2021. [DOI: 10.1016/b978-0-12-820779-6.00003-7] [Reference Citation Analysis]
30 Upadhaya P, Pulakkat S, Patravale V. Diagnostic and theranostic intranasal nanointerventions for brain diseases. Direct Nose-to-Brain Drug Delivery 2021. [DOI: 10.1016/b978-0-12-822522-6.00013-8] [Reference Citation Analysis]
31 Topal GR, Mészáros M, Porkoláb G, Szecskó A, Polgár TF, Siklós L, Deli MA, Veszelka S, Bozkir A. ApoE-Targeting Increases the Transfer of Solid Lipid Nanoparticles with Donepezil Cargo across a Culture Model of the Blood-Brain Barrier. Pharmaceutics 2020;13:38. [PMID: 33383743 DOI: 10.3390/pharmaceutics13010038] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
32 Yadollahpour A. Nanotechnology in Targeted Drug Delivery in Medical Theranostics: From Lab to Bed. Curr Top Med Chem 2020;20:2735-6. [PMID: 33292118 DOI: 10.2174/156802662030201110091740] [Reference Citation Analysis]
33 Augustine R, Hasan A, Primavera R, Wilson RJ, Thakor AS, Kevadiya BD. Cellular uptake and retention of nanoparticles: Insights on particle properties and interaction with cellular components. Materials Today Communications 2020;25:101692. [DOI: 10.1016/j.mtcomm.2020.101692] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 11.0] [Reference Citation Analysis]
34 Jhawat V, Gulia M, Gupta S, Maddiboyina B, Dutt R. Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy. J Control Release 2020;327:500-11. [PMID: 32858073 DOI: 10.1016/j.jconrel.2020.08.039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
35 De Vincentiis S, Falconieri A, Scribano V, Ghignoli S, Raffa V. Manipulation of Axonal Outgrowth via Exogenous Low Forces. Int J Mol Sci 2020;21:E8009. [PMID: 33126477 DOI: 10.3390/ijms21218009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
36 Binda A, Murano C, Rivolta I. Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer's Disease: A State-of-the-Art (2017-2020). Int J Nanomedicine 2020;15:6113-35. [PMID: 32884267 DOI: 10.2147/IJN.S231480] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
37 Thorat ND, Townley HE, Patil RM, Tofail SAM, Bauer J. Comprehensive approach of hybrid nanoplatforms in drug delivery and theranostics to combat cancer. Drug Discov Today 2020;25:1245-52. [PMID: 32371139 DOI: 10.1016/j.drudis.2020.04.018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
38 Bueno J. Synergy and Antagonism: The Criteria of the Formulation. Nanotechnology in the Life Sciences 2020. [DOI: 10.1007/978-3-030-43855-5_3] [Reference Citation Analysis]
39 Zhou Z, Ni K, Deng H, Chen X. Dancing with reactive oxygen species generation and elimination in nanotheranostics for disease treatment. Adv Drug Deliv Rev 2020;158:73-90. [PMID: 32526453 DOI: 10.1016/j.addr.2020.06.006] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 15.3] [Reference Citation Analysis]
40 Ciaglia E, Montella F, Trucillo P, Ciardulli M, Di Pietro P, Amodio G, Remondelli P, Vecchione C, Reverchon E, Maffulli N, Puca A, Della Porta G. A bioavailability study on microbeads and nanoliposomes fabricated by dense carbon dioxide technologies using human-primary monocytes and flow cytometry assay. International Journal of Pharmaceutics 2019;570:118686. [DOI: 10.1016/j.ijpharm.2019.118686] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
41 Lowe TL, Agrahari V, Kannan RM, Kannan S. Nanotechnology enabled regenerative medicine for neurological disorders. Adv Drug Deliv Rev 2019;148:1-2. [PMID: 31787167 DOI: 10.1016/j.addr.2019.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
42 Limongi T, Canta M, Racca L, Ancona A, Tritta S, Vighetto V, Cauda V. Improving dispersal of therapeutic nanoparticles in the human body. Nanomedicine (Lond) 2019;14:797-801. [PMID: 30895871 DOI: 10.2217/nnm-2019-0070] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
43 Bueno J. Nanotheranostics Approaches in Antimicrobial Drug Resistance. Nanotheranostics 2019. [DOI: 10.1007/978-3-030-29768-8_3] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
44 Ottemann BM, Helmink AJ, Zhang W, Mukadam I, Woldstad C, Hilaire JR, Liu Y, McMillan JM, Edagwa BJ, Mosley RL, Garrison JC, Kevadiya BD, Gendelman HE. Bioimaging predictors of rilpivirine biodistribution and antiretroviral activities. Biomaterials 2018;185:174-93. [PMID: 30245386 DOI: 10.1016/j.biomaterials.2018.09.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]